Q2 FY2026 · ended Jun 30, 2026 · Revenue $660,601, +12.0% YoY · Filed Aug 6, 2026
Xenetic Biosciences, Inc. (XBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $660,601 and a net loss of $929,695.
Revenue
$660,601
+12.0% vs year-ago quarter
Net income
$-929,695
-35.0% vs year-ago quarter
Operating cash flow
$-875,489
-128.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.41
+8.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.34M
+51.9% vs year-ago quarter
Net cash
—
Operating margin
-81.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Framingham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534525
- Former names
- General Sales & Leasing, Inc. (until Jan 10, 2014); GENERAL AIRCRAFT INC. (until Feb 12, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $660,601 | $806,923 | $766,296 | $1.0M | $589,897 |
| Operating income | -$971,690 | -$502,117 | -$623,027 | -$544,734 | -$724,412 |
| Net income | -$929,695 | -$456,382 | -$579,076 | -$509,940 | -$688,703 |
| Diluted EPS | -$0.41 | -$0.20 | -$0.27 | -$0.33 | -$0.45 |
| Operating cash flow | -$875,489 | -$536,377 | -$242,682 | -$658,247 | -$383,830 |
| Total assets | $7.0M | $7.9M | $8.4M | $5.1M | $5.4M |
| Total liabilities | $894,977 | $958,239 | $968,025 | $1.1M | $903,430 |
| Stockholders' equity | $6.1M | $7.0M | $7.4M | $4.0M | $4.5M |
| Cash and investments | $6.5M | $7.3M | $7.9M | $4.1M | $4.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 16, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 484 Xenetic Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.